SEC Filing Summary: Oculus Innovative Sciences, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on January 26, 2015, covering events occurring on January 20, 2015. The filing details the entry into a material definitive agreement for an underwritten public offering of common stock and warrants.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 6,250,000 shares of common stock and warrants to purchase 4,687,500 shares at an exercise price of $1.30 per share.
- Offering Price: $1.00 per share of common stock plus 0.75 of a warrant.
- Over-Allotment: Underwriters exercised an option to purchase an additional 703,125 warrants on January 21, 2015.
- Net Proceeds: Approximately $5.3 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Underwriting Fees: Cash fee of 8% of aggregate gross proceeds plus a non-accountable expense allowance up to $100,000 for legal fees and $25,000 for non-legal expenses.
- Representative's Warrants: Issuance of warrants to purchase 359,375 shares (5% of total shares sold) at an exercise price of $1.10 per share, subject to a 180-day lock-up.
Material Changes and Events
The primary material change is the completion of the capital raise on January 26, 2015. The warrants began trading on the NASDAQ Capital Market on January 21, 2015, under the symbol "OCLSW." The company entered into a six-month lock-up agreement regarding the sale of common stock by the company, its directors, and officers.
Outlook, Risks, and Contingencies
The filing contains forward-looking statements regarding the company's future activities and a planned spin-off, noting that actual results may differ due to risks discussed in the Form 10-K. The filing does not provide specific revenue, profit, cash flow, or debt metrics for the reporting period, as it focuses solely on the capital transaction. The company has agreed to customary indemnification obligations and termination provisions within the underwriting agreement.
Investor Verification Checklist
- Verify the final closing date of the offering (January 26, 2015) and the exact net proceeds received.
- Confirm the trading status and volume of the warrants under symbol "OCLSW" on the NASDAQ Capital Market.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific representations and warranties.
- Check the company's Form 10-K for detailed risk factors related to the planned spin-off mentioned in the forward-looking statements.
- Monitor the exercise of the remaining over-allotment option (if any) regarding the 937,500 shares of common stock.